Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15725091 | 0.89 | CA14 (0.40) | MEN1KMT2ACA14HDAC6HDAC1 | |
| SCHEMBL20989891 | 0.87 | CA14 (0.39) | MEN1KMT2ACA14HDAC6HDAC1 | |
| SCHEMBL19302428 | 0.87 | CA14 (0.39) | MEN1KMT2ACA14HDAC6HDAC1 | |
| SCHEMBL21012200 | 0.87 | CA14 (0.39) | MEN1KMT2ACA14HDAC6HDAC1 | |
| SCHEMBL17686995 | 0.87 | CA14 (0.39) | MEN1KMT2ACA14HDAC6HDAC1 | |
| SCHEMBL25960261 | 0.87 | CA14 (0.39) | MEN1KMT2ACA14HDAC6HDAC1 | |
| SCHEMBL10267170 | 0.87 | CA12 (0.43) | MEN1KMT2ACA14HDAC6HDAC1 | |
| SCHEMBL16965623 | 0.85 | MEN1 (0.45) | MEN1KMT2ACA14LMNACA12 | |
| SCHEMBL16925564 | 0.85 | MLYCD (0.42) | MEN1KMT2ACA14HDAC6HDAC1 | |
| SCHEMBL4164699 | 0.85 | CA14 (0.41) | MEN1KMT2ACA14HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078841-A2 | ANTIBODIES, CONJUGATES, AND USES THEREOF | ANTIKOR BIOPHARMA LIMITED (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20240390411-A1 | COMPOSITION COMPRISING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | SEIKAGAKU CORPORATION (JP) | 2024-11-28 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023107547-A2 | AZETIDINE AND SPIROAZETIDINE COMPOUNDS AND USES THEREOF | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | iTeos Belgium SA (BE) | 2023-05-25 | — | — | US | disclosed |
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | Wuxi Life Fountain Biotech Co., Ltd. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20220133776-A1 | COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | SEIKAGAKU CORPORATION (JP) | 2022-05-05 | — | — | US | disclosed |
| WO-2022091001-A1 | PROCESS FOR PREPARATION OF PALBOCICLIB | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-05-05 | — | — | WO | disclosed |
| CN-114405547-A | Metal complexes | 利兹大学 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022056042-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2007118276-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION(AMD) | PRANA BIOTECHNOLOGY LTD (AU) | 2007-10-25 | — | — | WO | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7279601-B2 | Optically active α-aminooxyketone derivatives and process for production thereof | TOKYO UNIVERSITY OF SCIENCE, CENTER FOR SCIENCE AND TECHNOLOGY EXCHANGE (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7279601-B2 | Optically active α-aminooxyketone derivatives and process for production thereof | TOKYO UNIVERSITY OF SCIENCE, CENTER FOR SCIENCE AND TECHNOLOGY EXCHANGE (JP) | 2007-10-09 | — | — | US | disclosed |
| US-7241763-B2 | 3-furanyl analogs of toxoflavine as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070027147-A1 | Biarylurea derivatives | MSD K.K. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-5110708-A | RADIATION-SENSITIVE MIXTURE AND PRODUCTION OF RELIEF IMAGES | BASF AKTIENGESELLSCHAFT (DE) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027147-A1 | Biarylurea derivatives | CDK6, CDK4, CCNI | MEN1 3166/4885KMT2A 218/4885CA14 3507/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | MEN1 2447/4885KMT2A 1208/4885CA14 1421/4885 |
| US-20230002360-A1 | Heterocycloalkyl compounds as CCR2 / CCR5 antagonists | CCR2, CCR5, CCRL2 | MEN1 3646/4885KMT2A 2936/4885CA14 3533/4885 |
| US-20240390411-A1 | COMPOSITION COMPRISING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | CCL5, CCL2, CCR5 | MEN1 4680/4885KMT2A 4547/4885CA14 1767/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | MEN1 3398/4885KMT2A 1306/4885CA14 2924/4885 |
| US-20220133776-A1 | COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | CCL5, CCL2, ACKR3 | MEN1 4555/4885KMT2A 4462/4885CA14 2205/4885 |
| US-20230159564-A1 | 2-Oxo-Thiazole Derivatives as A2A Inhibitors and Compounds for Use in the Treatment of Cancers | ADORA2A, ADORA2B, ADORA3 | MEN1 1214/4885KMT2A 2289/4885CA14 3060/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | MEN1 2672/4885KMT2A 2362/4885CA14 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.